Publications by authors named "Mathieu Nkieri Matsho"
Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study.
Victor Kande Betu Ku Mesu Wilfried Mutombo Kalonji Clélia Bardonneau Olaf Valverde Mordt Digas Ngolo Tete Mathieu Nkieri Matsho
Lancet Glob Health
July 2021
Article Synopsis
- This text discusses a study evaluating the safety and effectiveness of the oral drug fexinidazole for treating early stages of human African trypanosomiasis (g-HAT), which typically requires more invasive procedures like lumbar punctures and intravenous therapy.
- The study involved recruiting patients from eight treatment centers in the Democratic Republic of the Congo, focusing on those with stage 1 or early stage 2 g-HAT who met specific health criteria, while excluding those with severe health issues or contraindications.
- The goal of the research is to make treatment more accessible and less burdensome for patients in rural areas affected by this disease, highlighting the potential of fexinidazole as a convenient oral treatment option.